NCT07198724View on ClinicalTrials.gov

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2038

Conditions
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast CancerBreast CancerBreast Cancer Female
Interventions
DRUG

Elacestrant

Selective estrogen receptor degrader (SERD), film-coated tablet, taken orally per protocol.

DRUG

Trastuzumab Deruxtecan

HER2-directed antibody-drug conjugate, vial, via intravenous (into the vein) infusion per standard of care

Trial Locations (2)

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Stemline Therapeutics, Inc.

INDUSTRY

lead

Sarah Sammons, MD

OTHER